What is the recommended dose of co-amoxiclav (amoxicillin/clavulanic acid) for pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Co-Amoxiclav Dosing in Pediatric Patients

For most pediatric patients with acute infections, use high-dose co-amoxiclav at 90 mg/kg/day of the amoxicillin component with 6.4 mg/kg/day of clavulanate, divided into two daily doses (14:1 ratio formulation). 1

Age-Based Oral Dosing Regimens

Standard Suspension Dosing

  • <1 year (1-12 months): 2.5 ml three times daily of 125/31 suspension 2
  • 1-6 years: 5 ml three times daily of 125/31 suspension 2
  • 7-12 years: 5 ml three times daily of 250/62 suspension 2
  • 12-18 years: 1 tablet (250/125) three times daily 2

High-Dose Regimen (Preferred for Resistant Organisms)

The high-dose formulation provides superior coverage against penicillin-resistant Streptococcus pneumoniae and β-lactamase-producing organisms 1. This regimen is specifically indicated for:

  • Children <2 years of age 1
  • Recent antibiotic use within 30 days 2, 1
  • Daycare attendance 1
  • Concurrent conjunctivitis 2
  • Moderate to severe illness 1
  • Incomplete Haemophilus influenzae type b vaccination (<3 injections) 1

The 90 mg/kg/day amoxicillin component achieves middle ear fluid concentrations adequate to overcome resistant pathogens, while standard 40-45 mg/kg/day dosing leads to treatment failure with resistant organisms 1, 3.

Intravenous Dosing

  • All ages: 30 mg/kg three times daily IV 2

Clinical Pharmacology Considerations

Dosing Rationale

High-dose amoxicillin (80-90 mg/kg/day) exceeds the minimum inhibitory concentration for intermediately resistant S. pneumoniae (penicillin MICs 0.12-1.0 μg/mL) and many highly resistant serotypes (penicillin MICs ≥2 μg/mL) for longer periods during the dosing interval 2. The 14:1 ratio formulation (90/6.4 mg/kg/day) causes less diarrhea than other amoxicillin-clavulanate preparations while maintaining efficacy 2, 1.

Maximum Dosing

The maximum single dose is 2 grams per dose regardless of weight 1.

Alternative Dosing for Specific Infections

For β-lactamase-producing H. influenzae in respiratory tract infections, either 45 mg/kg/day in 3 doses or 90 mg/kg/day in 2 doses is acceptable 1. However, the twice-daily high-dose regimen is preferred for improved compliance and equivalent efficacy 1.

Duration of Therapy

Treatment courses should be 10 days for most pediatric infections 1, or continue for 7 days after the patient becomes free of signs and symptoms 1.

Common Pitfalls to Avoid

Using standard doses (40-45 mg/kg/day) when high-dose therapy is indicated will result in treatment failure with resistant organisms 1. This is particularly problematic in areas with >10% prevalence of penicillin-resistant S. pneumoniae 1.

The older three-times-daily dosing regimens from pandemic influenza guidelines 2 are now superseded by twice-daily high-dose formulations that provide better compliance and equivalent or superior efficacy 1.

Serum levels of amoxicillin increase linearly with dose, and the difference in adverse effects between lower and higher doses is generally negligible 1. Common adverse effects include diarrhea, nausea, vomiting, and rash, but these are less frequent with the twice-daily high-dose formulation 1.

References

Guideline

Amoxicillin-Clavulanate Dosing in Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.